{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:31:06Z","timestamp":1793662266011,"version":"4.5.1"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Incidence of distant stage prostate cancer is increasing in the United States. Research is needed to understand trends by social and geographic factors.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine trends in prostate cancer incidence and mortality rates in California by stage, age, race and ethnicity, and region.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study used mortality data from the California Cancer Registry and California Department of Public Health's Center for Health Statistics, and incidence data from the National Cancer Institute Surveillance, Epidemiology, and End Results program and the US Census. The dataset for these analyses was released in April 2024. Participants included males residing in California between 2004 and 2021. Analyses were conducted from April to October 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Stage at diagnosis, age, race and ethnicity, and region of California.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The delay-adjusted incidence rates and mortality rates were calculated and age-adjusted to the 2000 US standard population. Annual percentage changes (APC) were calculated using NCI\u2019s Joinpoint Regression Program.<\/jats:p><\/jats:sec>Results<\/jats:title>Between 2004 and 2021, there were 387\u202f636 prostate cancer cases (27\u202f938 distant stage) and 58\u202f754 prostate cancer deaths in California. In this study, 203\u202f038 cases (52.4%) occurred among males aged 55 to 69 years, and 153\u202f884 (39.7%) occurred among males 70 years or older. The distribution of race and ethnicity among cases was: 1031 American Indian or Alaska Native (0.3%); 31\u202f366 Asian American, Native Hawaiian, and Pacific Islander (8.1%); 66\u202f695 Hispanic or Latino (17.2%); 36\u202f808 non-Hispanic Black (9.5%); 238\u202f229 non-Hispanic White (61.5%); and 13\u202f507 unknown or other races (3.5%). On average, the incidence of distant prostate cancer increased 6.7% (95% CI, 6.2% to 7.3%) per year between 2011 and 2021. By race and ethnicity, the APC ranged from 6.5% (95% CI, 4.2% to 13.4%) among Asian American, Native Hawaiian, and Pacific Islander males between 2011 and 2021 to 8.0% (95% CI, 6.9% to 9.5%) among Hispanic males between 2014 and 2021. In 9 of the 10 California regions, the incidence of distant prostate cancer increased by approximately 6% or more per year. Prostate cancer mortality rates declined 2.6% per year between 2004 and 2012 but plateaued between 2012 to 2021 (APC, 0.1%; 95% CI, \u22120.6% to 1.6%). The plateau in mortality occurred across ages, races and ethnicities, and regions.<\/jats:p><\/jats:sec>Conclusions and relevance<\/jats:title>In this cohort study among California residents, the incidence of distant stage prostate cancer increased throughout the state between 2011 and 2021. Mortality rates plateaued between 2012 and 2021, ending previous decades of decline. Implementation of more effective prostate cancer screening strategies are critically needed.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.56825","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T16:33:51Z","timestamp":1737995631000},"page":"e2456825","source":"Crossref","is-referenced-by-count":48,"title":["Trends in Prostate Cancer Incidence and Mortality Rates"],"prefix":"10.1001","volume":"8","author":[{"given":"Erin L.","family":"Van Blarigan","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"},{"name":"Department of Urology, University of California, San Francisco"},{"name":"Greater Bay Area Cancer Registry, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg A.","family":"McKinley","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"},{"name":"Greater Bay Area Cancer Registry, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Samuel L.","family":"Washington","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"},{"name":"Department of Urology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"},{"name":"Department of Urology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey A.","family":"Kenfield","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"},{"name":"Department of Urology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"},{"name":"Greater Bay Area Cancer Registry, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scarlett L.","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"},{"name":"Greater Bay Area Cancer Registry, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"1","key":"zoi241591r2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"zoi241591r3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3322\/caac.21718","article-title":"Cancer statistics for African American\/Black People 2022.","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi241591r4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.eururo.2022.11.023","article-title":"Disparities and trends in genitourinary cancer incidence and mortality in the USA.","volume":"84","author":"Schafer","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"zoi241591r6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eururo.2020.09.041","article-title":"An up-to-date assessment of US prostate cancer incidence rates by stage and race: a novel approach combining multiple imputation with age and delay adjustment.","volume":"79","author":"Cook","year":"2021","journal-title":"Eur Urol"},{"issue":"20","key":"zoi241591r7","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/jnci\/94.20.1537","article-title":"Impact of reporting delay and reporting error on cancer incidence rates and trends.","volume":"94","author":"Clegg","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"zoi241591r9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10552-022-01557-y","article-title":"Home mortgage discrimination and incidence of triple-negative and Luminal A breast cancer among non-Hispanic Black and non-Hispanic White females in California, 2006-2015.","volume":"33","author":"Michaels","year":"2022","journal-title":"Cancer Causes Control"},{"issue":"9","key":"zoi241591r12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/jnci\/djad086","article-title":"Interpreting cancer incidence trends: challenges due to the COVID-19 pandemic.","volume":"115","author":"Mariotto","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi241591r15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cncr.34530","article-title":"Patient perspectives of prostate cancer screening vary by race following 2018 guideline changes.","volume":"129","author":"Riviere","year":"2023","journal-title":"Cancer"},{"issue":"3","key":"zoi241591r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.2852","article-title":"Neighborhood deprivation, race and ethnicity, and prostate cancer outcomes across California health care systems.","volume":"7","author":"Wadhwa","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi241591r17","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/cncr.32666","article-title":"Survival of African American and non-Hispanic White men with prostate cancer in an equal-access health care system.","volume":"126","author":"Riviere","year":"2020","journal-title":"Cancer"},{"key":"zoi241591r18","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae109","article-title":"County-level racial disparities in prostate cancer specific mortality from 2005 to 2020.","author":"Washington","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"key":"zoi241591r1","unstructured":"U.S. Preventive Services Task Force. Prostate cancer: screening. Accessed January 7, 2025. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/prostate-cancer-screening"},{"key":"zoi241591r5","unstructured":"SEER*Stat Software. National Cancer Institute. Accessed December 23, 2024. https:\/\/seer.cancer.gov\/seerstat\/"},{"key":"zoi241591r8","unstructured":"California all cause mortality 1970-2021. California Cancer Registry. Accessed December 23, 2024. https:\/\/www.ccrcal.org\/retrieve-data\/data-for-the-public\/"},{"key":"zoi241591r10","unstructured":"US county population data\u20141969-2022. National Cancer Institute. Accessed December 23, 2024. https:\/\/seer.cancer.gov\/popdata\/"},{"key":"zoi241591r11","unstructured":"Regions. California Census 2020. Accessed January 2, 2025. https:\/\/census.ca.gov\/regions\/"},{"key":"zoi241591r13","unstructured":"APC\/AAPC\/Tau confidence intervals. National Cancer Institute. Accessed December 13, 2024. https:\/\/surveillance.cancer.gov\/"},{"key":"zoi241591r14","unstructured":"AACR cancer disparities progress report. American Association for Cancer Research. Accessed June 19, 2024. https:\/\/www.aacr.org\/patients-caregivers\/aacrs-impact\/aacr-cancer-disparities-progress-report\/"},{"key":"zoi241591r19","unstructured":"SEER stat fact sheets: prostate cancer. National Cancer Institute. Accessed July 9, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2829547\/van_blarigan_2025_oi_241591_1737127967.79085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T16:33:55Z","timestamp":1737995635000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2829547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56825","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}